BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] Presentation Details - BioAtla will present two preclinical posters at the 2025 American Association for Cancer Research (AACR) conference in Chicago from April 25–30, 2025 [1][2] - The first poster discusses novel senolytic targets and CAB-based drug conjugates for eliminating senescence-associated secretory phenotype cells [2] - The second poster highlights BA3361, a tumor-selective CAB anti-Nectin4 antibody-drug conjugate that enhances therapeutic efficacy in pancreatic cancer [2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, utilizing its proprietary CAB platform technology to develop monoclonal and bispecific antibodies [3] - The CAB technology aims for selective targeting, greater efficacy with lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - The company holds over 780 active patent matters, with more than 500 issued patents covering its CAB technology and products [3][4] Technology Highlights - The CAB anti-Nectin4-ADC shows differentiated preclinical activity with superior efficacy compared to enfortumab vedotin in various cancer models [4] - CAB technology offers a new generation of biologics with an increased safety margin and therapeutic index, targeting senescence-related cells in cancer and age-related diseases [4]